Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model

Mihwa Shin, Hirofumi Hino, Midori Tamura, Bunpei Ishizuka, Mamoru Tanaka, Nao Suzuki, Takeshi Tateda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: The aim of this study was to investigate whether the consecutive administration of recombinant thrombomodulin (r-TM) for 4 days improves maternal and fetal conditions and physiological outcomes in an N'-nitro-L-arginine- methyl ester hydrochloride-induced and low-dose endotoxin-induced pre-eclampsia (PE). Methods: r-TM or saline was administrated i.v. to normal pregnant and experimental PE rats for 4 days. The maternal condition, vascular endothelial growth factor receptor-1 (VEGFR-1), fetal conditions, uteroplacental blood flow (UPBF), and oxygenation in the placenta and fetal brain was evaluated on gestational day 21. Results: Significant increases in the mean arterial blood pressure, VEGFR-1 values and fetal death rate were observed in PE rats compared with control rats, while maternal and fetal bodyweight and fetal brain weight were substantially lower. Hypoperfusion and hypo-oxygenation in both the placenta and fetal brain tissues occurred in PE rats. Although r-TM failed to improve hypertension and affect the differences in maternal bodyweight between the groups, r-TM significantly improved hypoperfusion and fetal and maternal conditions, including VEGFR-1 values (6.5 ± 4.0 vs 2.2 ± 2.7 ng/mL, PE vs PE with r-TM, respectively; P < 0.05). Although not significant, a decrease in the fetal death rate was observed in PE rats administrated r-TM (36.1 ± 17.6% vs 25.0 ± 23.8%, P = 0.077). Conclusion: The severe reductions in the UPBF and the placental oxygenation imply that regional hypoperfusion occurs in association with systemic mean arterial pressure. r-TM may be a candidate medical treatment for PE complications.

Original languageEnglish
Pages (from-to)1226-1234
Number of pages9
JournalJournal of Obstetrics and Gynaecology Research
Volume40
Issue number5
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Thrombomodulin
Pre-Eclampsia
Mothers
Vascular Endothelial Growth Factor Receptor-1
Arterial Pressure
Fetal Death
Placenta
Brain
Fetal Weight
Mortality
Endotoxins
Arginine
Fetus
Hypertension

Keywords

  • Fetal growth restriction
  • Pre-eclampsia
  • Recombinant thrombomodulin
  • Uteroplacental circulation
  • Vascular endothelial growth factor receptor-1

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Medicine(all)

Cite this

Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model. / Shin, Mihwa; Hino, Hirofumi; Tamura, Midori; Ishizuka, Bunpei; Tanaka, Mamoru; Suzuki, Nao; Tateda, Takeshi.

In: Journal of Obstetrics and Gynaecology Research, Vol. 40, No. 5, 2014, p. 1226-1234.

Research output: Contribution to journalArticle

Shin, Mihwa ; Hino, Hirofumi ; Tamura, Midori ; Ishizuka, Bunpei ; Tanaka, Mamoru ; Suzuki, Nao ; Tateda, Takeshi. / Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model. In: Journal of Obstetrics and Gynaecology Research. 2014 ; Vol. 40, No. 5. pp. 1226-1234.
@article{df16d016df9a44f6ad05f09b3af57354,
title = "Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model",
abstract = "Aim: The aim of this study was to investigate whether the consecutive administration of recombinant thrombomodulin (r-TM) for 4 days improves maternal and fetal conditions and physiological outcomes in an N'-nitro-L-arginine- methyl ester hydrochloride-induced and low-dose endotoxin-induced pre-eclampsia (PE). Methods: r-TM or saline was administrated i.v. to normal pregnant and experimental PE rats for 4 days. The maternal condition, vascular endothelial growth factor receptor-1 (VEGFR-1), fetal conditions, uteroplacental blood flow (UPBF), and oxygenation in the placenta and fetal brain was evaluated on gestational day 21. Results: Significant increases in the mean arterial blood pressure, VEGFR-1 values and fetal death rate were observed in PE rats compared with control rats, while maternal and fetal bodyweight and fetal brain weight were substantially lower. Hypoperfusion and hypo-oxygenation in both the placenta and fetal brain tissues occurred in PE rats. Although r-TM failed to improve hypertension and affect the differences in maternal bodyweight between the groups, r-TM significantly improved hypoperfusion and fetal and maternal conditions, including VEGFR-1 values (6.5 ± 4.0 vs 2.2 ± 2.7 ng/mL, PE vs PE with r-TM, respectively; P < 0.05). Although not significant, a decrease in the fetal death rate was observed in PE rats administrated r-TM (36.1 ± 17.6{\%} vs 25.0 ± 23.8{\%}, P = 0.077). Conclusion: The severe reductions in the UPBF and the placental oxygenation imply that regional hypoperfusion occurs in association with systemic mean arterial pressure. r-TM may be a candidate medical treatment for PE complications.",
keywords = "Fetal growth restriction, Pre-eclampsia, Recombinant thrombomodulin, Uteroplacental circulation, Vascular endothelial growth factor receptor-1",
author = "Mihwa Shin and Hirofumi Hino and Midori Tamura and Bunpei Ishizuka and Mamoru Tanaka and Nao Suzuki and Takeshi Tateda",
year = "2014",
doi = "10.1111/jog.12323",
language = "English",
volume = "40",
pages = "1226--1234",
journal = "Asia-Oceania Journal of Obstetrics and Gynaecology",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "5",

}

TY - JOUR

T1 - Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model

AU - Shin, Mihwa

AU - Hino, Hirofumi

AU - Tamura, Midori

AU - Ishizuka, Bunpei

AU - Tanaka, Mamoru

AU - Suzuki, Nao

AU - Tateda, Takeshi

PY - 2014

Y1 - 2014

N2 - Aim: The aim of this study was to investigate whether the consecutive administration of recombinant thrombomodulin (r-TM) for 4 days improves maternal and fetal conditions and physiological outcomes in an N'-nitro-L-arginine- methyl ester hydrochloride-induced and low-dose endotoxin-induced pre-eclampsia (PE). Methods: r-TM or saline was administrated i.v. to normal pregnant and experimental PE rats for 4 days. The maternal condition, vascular endothelial growth factor receptor-1 (VEGFR-1), fetal conditions, uteroplacental blood flow (UPBF), and oxygenation in the placenta and fetal brain was evaluated on gestational day 21. Results: Significant increases in the mean arterial blood pressure, VEGFR-1 values and fetal death rate were observed in PE rats compared with control rats, while maternal and fetal bodyweight and fetal brain weight were substantially lower. Hypoperfusion and hypo-oxygenation in both the placenta and fetal brain tissues occurred in PE rats. Although r-TM failed to improve hypertension and affect the differences in maternal bodyweight between the groups, r-TM significantly improved hypoperfusion and fetal and maternal conditions, including VEGFR-1 values (6.5 ± 4.0 vs 2.2 ± 2.7 ng/mL, PE vs PE with r-TM, respectively; P < 0.05). Although not significant, a decrease in the fetal death rate was observed in PE rats administrated r-TM (36.1 ± 17.6% vs 25.0 ± 23.8%, P = 0.077). Conclusion: The severe reductions in the UPBF and the placental oxygenation imply that regional hypoperfusion occurs in association with systemic mean arterial pressure. r-TM may be a candidate medical treatment for PE complications.

AB - Aim: The aim of this study was to investigate whether the consecutive administration of recombinant thrombomodulin (r-TM) for 4 days improves maternal and fetal conditions and physiological outcomes in an N'-nitro-L-arginine- methyl ester hydrochloride-induced and low-dose endotoxin-induced pre-eclampsia (PE). Methods: r-TM or saline was administrated i.v. to normal pregnant and experimental PE rats for 4 days. The maternal condition, vascular endothelial growth factor receptor-1 (VEGFR-1), fetal conditions, uteroplacental blood flow (UPBF), and oxygenation in the placenta and fetal brain was evaluated on gestational day 21. Results: Significant increases in the mean arterial blood pressure, VEGFR-1 values and fetal death rate were observed in PE rats compared with control rats, while maternal and fetal bodyweight and fetal brain weight were substantially lower. Hypoperfusion and hypo-oxygenation in both the placenta and fetal brain tissues occurred in PE rats. Although r-TM failed to improve hypertension and affect the differences in maternal bodyweight between the groups, r-TM significantly improved hypoperfusion and fetal and maternal conditions, including VEGFR-1 values (6.5 ± 4.0 vs 2.2 ± 2.7 ng/mL, PE vs PE with r-TM, respectively; P < 0.05). Although not significant, a decrease in the fetal death rate was observed in PE rats administrated r-TM (36.1 ± 17.6% vs 25.0 ± 23.8%, P = 0.077). Conclusion: The severe reductions in the UPBF and the placental oxygenation imply that regional hypoperfusion occurs in association with systemic mean arterial pressure. r-TM may be a candidate medical treatment for PE complications.

KW - Fetal growth restriction

KW - Pre-eclampsia

KW - Recombinant thrombomodulin

KW - Uteroplacental circulation

KW - Vascular endothelial growth factor receptor-1

UR - http://www.scopus.com/inward/record.url?scp=84903647843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903647843&partnerID=8YFLogxK

U2 - 10.1111/jog.12323

DO - 10.1111/jog.12323

M3 - Article

C2 - 24689942

AN - SCOPUS:84903647843

VL - 40

SP - 1226

EP - 1234

JO - Asia-Oceania Journal of Obstetrics and Gynaecology

JF - Asia-Oceania Journal of Obstetrics and Gynaecology

SN - 1341-8076

IS - 5

ER -